| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S81467-1mg买3赠1 |
98.60% | ￥142.00 |
7 | - | - | - | - |
|
S81467-2mg买3赠1 |
98.60% | ￥238.00 |
9 | - | - | - | - |
|
S81467-5mg促销 |
98.60% | ￥408.00 ￥326.00 |
9 | - | - | - | - |
|
S81467-10mg促销 |
98.60% | ￥544.00 ￥435.00 |
7 | - | - | - | - |
|
S81467-25mg促销 |
98.60% | ￥1080.00 ￥864.00 |
2 | - | - | - | - |
|
S81467-50mg促销 |
≥98% | ￥1490.00 ￥1340.00 |
货期：2-3天 | - | - | - | - |
|
S81467-100mg |
≥98% | ￥2040.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | p110α:8 nM (IC50);p110β:88 nM (IC50);p110δ:48 nM (IC50);p110γ:150 nM (IC50);mTORC1:20 nM (IC50);mTORC2:83 nM (IC50);PI3KC2β:26 nM (IC50);PI3KC2α:1 μM (IC50);hsVPS34:2.3 μM (IC50);DNA-PK:2 nM (IC50);ATR:850 nM (IC50);ATM:920 nM (IC50);PI4KIIIβ:50 μM (IC50);Apoptosis; DNA-PK; PI3K; mTOR; Autophagy | ||||||||||||||||||||
| 体内研究： | PI-103 shows therapeutic activity against a range of human tumor xenografts, exhibiting inhibition of angiogenesis, invasion, and metastasis, as well as direct antiproliferative effects. PI-103 induces immunosuppression promoting in vivo tumor growth and inhibiting apoptosis. Tumors from PI-103-treated mice shows higher levels of cyclin D1 and more proliferating cells | ||||||||||||||||||||
| 参考文献： | 1. Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39. 2. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47. 3. Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706. 4. López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61. | ||||||||||||||||||||
| 溶解性： | DMSO : 10 mg/mL (28.71 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
